Surmodics, Inc. (NASDAQ:SRDX) VP Charles W. Olson sold 801 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $27.85, for a total transaction of $22,307.85. Following the sale, the vice president now owns 26,585 shares in the company, valued at approximately $740,392.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Surmodics, Inc. (NASDAQ SRDX) traded up 0.50% during trading on Tuesday, reaching $30.05. 56,475 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $26.12 and its 200-day moving average price is $25.10. Surmodics, Inc. has a one year low of $21.90 and a one year high of $30.75. The stock has a market cap of $393.93 million, a P/E ratio of 65.47 and a beta of 0.85.
Surmodics (NASDAQ:SRDX) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $0.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.10. Surmodics had a net margin of 8.66% and a return on equity of 7.28%. The business had revenue of $17.80 million for the quarter, compared to analysts’ expectations of $15.98 million. During the same period in the prior year, the company posted $0.37 EPS. The business’s revenue for the quarter was down 11.0% on a year-over-year basis. On average, equities analysts anticipate that Surmodics, Inc. will post $0.31 earnings per share for the current fiscal year.
WARNING: This piece was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/09/19/surmodics-inc-srdx-vp-charles-w-olson-sells-801-shares.html.
Several large investors have recently bought and sold shares of the company. Trigran Investments Inc. grew its stake in shares of Surmodics by 17.6% during the 2nd quarter. Trigran Investments Inc. now owns 1,258,613 shares of the company’s stock worth $35,430,000 after purchasing an additional 188,114 shares during the period. Wellington Management Group LLP grew its stake in shares of Surmodics by 8.7% during the 1st quarter. Wellington Management Group LLP now owns 1,174,839 shares of the company’s stock worth $28,255,000 after purchasing an additional 94,388 shares during the period. Renaissance Technologies LLC grew its stake in shares of Surmodics by 4.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,002,721 shares of the company’s stock worth $24,115,000 after purchasing an additional 38,683 shares during the period. Vanguard Group Inc. grew its stake in shares of Surmodics by 3.3% during the 2nd quarter. Vanguard Group Inc. now owns 717,091 shares of the company’s stock worth $20,187,000 after purchasing an additional 22,977 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Surmodics by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 630,777 shares of the company’s stock worth $17,756,000 after purchasing an additional 30,356 shares during the period. 84.85% of the stock is currently owned by institutional investors and hedge funds.
Several analysts recently commented on the stock. ValuEngine lowered shares of Surmodics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. BidaskClub upgraded shares of Surmodics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Lake Street Capital assumed coverage on shares of Surmodics in a research report on Friday, July 14th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Aegis assumed coverage on shares of Surmodics in a report on Tuesday, June 27th. They set a “buy” rating on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $34.33.
Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.
Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.